In a 13D filing on Amylin Pharmaceuticals, Inc. (AMLN), Carl Icahn disclosed he raised his stake in the company to 6.54% (8,959,919 shares). This is up from the 6,339,653 share stake Icahn showed in a recent 13F for the quarter ended March 31, 2008.
Icahn disclosed that he recently had discussions with the company's management and intends to have further conversations with management and members of the board of directors to discuss ideas they may have to maximize product sales and development and to enhance shareholder value.
Icahn said he reserves the right to take whatever future action he deems appropriate regarding the company and its securities under the circumstances as they then exist.
